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Abstract 
Introduction  
Orthostatic hypotension and presyncope are common and potentially serious risks for 
astronauts returning from space.  Susceptible subjects fail to generate an adequate 
adrenergic response to upright posture.  The α-1 adrenergic agonist, midodrine, may be 
an effective countermeasure. We tested the hypothesis that midodrine would have no 
negative hemodynamic effect on healthy astronauts returning from space.    
Methods 
Five male astronauts participated in preflight and postflight tilt testing on a control flight 
as well as on the test flights, where midodrine (10 mg, orally) was administered after 
landing, ~1 hour before testing.   
Results 
None of these astronauts exhibited orthostatic hypotension or presyncope before or after 
either flight.  Midodrine did not cause any untoward reactions in these subjects before or 
after flight, in fact a modest beneficial effect was seen on postflight tachycardia (p 
=0.036). 
Discussion 
These data show that midodrine protected against post-spaceflight increases in heart rate, 
without having any adverse hemodynamic effects on non-presyncopal, male astronauts.  
Among these subjects, midodrine was a safe cardiovascular countermeasure. 
 
 
Key words:  orthostatic intolerance, microgravity, α1 adrenergic agonist, de-
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Introduction 
 Orthostatic intolerance affects virtually every astronaut upon their return to earth.  
In roughly 80 % of crew members, this manifests as a standing heart rate that is 
significantly elevated over preflight levels.  In about 20% of Shuttle astronauts symptoms 
of orthostatic intolerance result in orthostatic hypotension (absolute standing systolic 
pressure < 70 mmHg)) and presyncope (light headedness, dizziness or nausea sufficient 
to terminate test) during postflight tilt tests (14).  Presyncopal subjects also experience  
lower resistance, lower systolic and diastolic pressure and higher heart rates on landing 
day than their non-presyncopal counterparts (14,15,22).  All astronauts who do not 
experience presyncope generate a hyperadrenergic response (increased plasma 
norepinephrine) to tilt testing on landing day, while the astronauts who become 
presyncopal do not (7,15). These findings led us to hypothesize that post-spaceflight 
orthostatic hypotension could be ameliorated with an α-1 adrenergic agonist to act in 
place of the norepinephrine, close to or after landing.  
 Midodrine is an α-1 adrenergic agonist that is used clinically to treat orthostatic 
hypotension.  There are a number of reports showing its usefulness in treating 
hypotensive disorders including;  exercise-induced hypotension (20), dialysis-induced 
hypotension (11,18), autonomic failure (9,16), and neurally mediated syncope (2,10).  
We proposed that midodrine would also be effective in treating, or preventing, post-
spaceflight orthostatic hypotension.  According to the package insert, the most common 
side effects of midodrine include parathesia (18.3%), piloerection (13.4%), dysuria 
(13.4%), pruritis (12.2 %) and supine hypertension (7.3%).  Countermeasures in our 
unique situation will be given in a remote setting, the final hour of spaceflight, without 
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the possibility of direct intervention if some adverse side effect or interaction occurs.   
Thus spaceflight-based countermeasures must correct a symptom in the target group, 
without creating new symptoms in the target or non-target group.  If midodrine is to 
become a prophylactic countermeasure it has to be safe for use in all crewmembers, 
including rookies, thus it must prevent postflight orthostatic hypotension in susceptible 
astronauts without causing hypertension (increased systolic BP > 30 mmHg) in non-
susceptible astronauts.  Accordingly, it must be tested in both of those groups.  Here we 
hypothesize that oral administration of midodrine (10 mg) will not cause a significant 
increase in arterial pressure. 
   We have previously reported that midodrine, taken 1 hour before the tilt test on 
landing day, prevented orthostatic hypotension in an astronaut who had been susceptible 
on a prior flight (17).  We now report results from five astronauts who volunteered for 
this study but had not been susceptible to orthostatic hypotension or presyncope 
following their previous space flights.  Comparisons were made between the 
hemodynamic responses during tilt/stand testing following flights with and without 
midodrine.    
Methods 
This study included both retrospective and prospective aspects.  Retrospectively, 
we used data from tilt or stand tests that had been performed on astronauts as a part of an 
earlier research protocol or as part of a test performed for medical operations.  From 
those results, astronauts were identified who had completed landing day tilt tests without 
symptoms of hypotension or presyncope.  Then, as those crew members were assigned to 
upcoming flights, we asked them to take midodrine on landing day as the prospective part 
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of the study.  Thus tilt/stand test data from the prior flights (control flight) were compared 
with tilt test data from the new flights (midodrine flight).  
Subjects  
 We identified astronauts who had previously flown in space and for whom we had 
tilt test data, and thus knew if they were susceptible to postflight orthostatic hypotension 
and presyncope.   From this group, five veteran, male astronauts volunteered to 
participate in our study. This approach was appropriate because postflight tilt test 
outcomes are highly reproducible from flight to flight (12).  All subjects gave written, 
informed consent to participate in this protocol, which was approved by the Johnson 
Space Center Committee for the Protection of Human Subjects.   
 Subjects returned to earth in the seated position following short duration space 
flights averaging 11.86 ± 0.81 days.  Upon arrival, astronauts were assisted off the orbiter 
and onto the crew transport vehicle where they were de-suited.  Crew members were then 
transported back to the data collection facility.  During transport crew members were 
ambulatory and were allowed to consume water ad libitum.  Midodrine was given as soon 
as the crew members arrived at the data collection facility (about 2 hours after landing).  
Post-flight activities were similar for all flights.  
 There were no changes in either arterial pressure or heart rate during the 
midodrine tolerance tests. The time between the 1st flight (control flight) and the 2nd flight 
(midodrine flight) was 53.8 ± 10.7 months.  Median flight duration for the midodrine 
flights was 10.3 days while the median for the control flights was 12.8 days.   While 
height and weight did not vary between flights, BMI’s were significantly higher 
following the midodrine flight (24.22 ± 1.52 vs 26.42 ± 1.7, p ≤0.05) as was age (45.62 ± 
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1.3 vs 50.2 ± 1.42 years p ≤0.05) . Other than mild piloerection, no side effects associated 
with midodrine were observed in the course of this study.    
Midodrine tolerance 
 When midodrine is administered orally, the peak plasma concentration of the 
active metabolite (deglymidodrine) occurs between 60 and 90 minutes with a half life of 
between 2-4 hours (8,23).  There is minimal effect of a single dose of midodrine on 
normal, healthy individuals, although a slight increase in systolic blood pressure is 
sometimes seen (8,23).  About three months before flight the astronauts came to the 
laboratory for a midodrine tolerance test.   Although midodrine has not been directly 
linked to cardiac dysrhythmias, midodrine, along with other adrenergic agonists, is 
listed by the Arizona Center for Education and Research on Therapeutics as 
potentially causing a risk of  ventricular dysrrhythmias (e.g. Torsades de Pointes) in 
subjects with a prolonged Q-Tc interval (>0.46 seconds)(1,21). Thus, as a precaution, 
a 12-lead ECG was taken and the Q-Tc interval was measured.  If it was < 0.46 seconds, a 
single 10 mg dose of midodrine was administered orally and the subjects were monitored 
every 15 minutes for brachial artery blood pressure and heart rate, while they went about 
their normal activities for 4 hours.  Subjects were also monitored for side effects due to 
midodrine.   No subjects were excluded from this study due to Q-Tc interval or any 
adverse reaction to midodrine.  
 Protocol 
     Tilt/stand tests were performed ten days before flight and about 3 hours after 
landing.  During a 5 minute supine rest period, ECG, finger blood pressure (beat-to-beat), 
brachial artery blood pressure (every minute) and stroke volume (Doppler ultrasound of 
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ascending aorta) were measured.  Then the subjects were moved to the upright posture by 
one of two methods: following the control flight, three subjects had their shoulders lifted 
off the bed, while their feet were swept off the bed by investigators (stand test), The 
remaining two subjects had tilt tests done after the control flight where an automatic tilt 
table was used to tilt the subjects passively to 80º for 10 minutes, during which all 
measurements continued.  All subjects underwent tilt testing before and after the 
midodrine flight.  Previous published work from this laboratory has shown that the stand 
tests and tilt tests elicit orthostatic hypotension and presyncope at statistically 
indistinguishable rates (14).   
 Every attempt was made to match protocols between the control and midodrine 
flights. For all flights, the astronauts performed the standard oral fluid load (equivalent to 
isotonic saline at 15 ml/kg within 2 hours) prior to landing, and had their anti-gravity 
suits fully inflated (1.5 psi).  The subjects abstained from caffeine, alcohol, and 
medications for 12 hours before the test session; were at least 2 hours postprandial; and 
had not exercised maximally 24 hours before testing.  The main differences in protocols 
between the control and midodrine flights were as follows.  After the control flights, no 
pharmacological countermeasures were used; after the midodrine flights a single 10 mg 
dose of midodrine was given following landing, and ~1 hour before the tilt test was 
performed.  Because there is some evidence that space flight can effect Q-Tc interval (5), 
a conservative approach was taken and after the midodrine flights, an additional 12-lead 
ECG was performed before midodrine administration to verify that the Q-Tc interval was 
< 0.46 seconds.  A catheter was inserted into an antecubital vein for blood collection.  
Blood was collected for a baseline measure and then every 15 minutes to measure the 
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concentration of midodrine and de-glymidodrine, the active metabolite (Bioassay 
Laboratory, Inc. Houston, TX). The subjects were placed supine on the table and the 
tilt/stand test was performed so that they were tilted as close to 1 hour after midodrine 
ingestion as possible .  
Analysis and statistics 
 Stroke volumes were obtained by measuring the aortic blood flow with Doppler 
ultrasound after the method of Childs et.al. (4).  All measurements were made by highly 
trained sonographers that are registered by the American Registry of Diagnostic Medical 
Sonographers, each having greater than 15 years of echo Doppler experience. In order to 
reduce operator bias during doppler analysis, all of the data was analyzed by two 
independent sonographers who were blinded to the test parameters.  These data were 
averaged to produce the final stroke volumes.   
 Heart rate was calculated from the electrocardiogram.  Cardiac output was 
calculated as (stroke volume x heart rate) and total peripheral resistance (TPR) was 
calculated as (mean arterial pressure/cardiac output).  All results are presented as means ± 
SE unless otherwise indicated.  Statistical analyses were performed using a commercially 
available software package (SigmaStat v. 3.0).  All data were tested for normalcy and 
equal variance using the Kolmogorov-Smirnov test and the Levene Median test, 
respectively. Differences were determined using either a one-tailed, paired  t-test (vital 
statistics as well as supine and 10 minute value if the ANOVA showed significance) or a 
1-way repeated measures analysis of variance (control vs midodrine or pre-flight vs 
landing day time curves).  Comparisons were considered significant if P ≤ 0.05. 
Results  
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Tilt test responses 
Systolic pressure (108 ± 2.87 vs 119  ±  3.99 mmHg) , diastolic pressure (74.8 ± 4.55 vs 
80.4 ± 1.63 mmHg) and cardiac output (2.82 ± 0.40 vs  2.45 ± 0.26 l/min) during 
tilt/stand tests were similar between control and midodrine flights respectively (10 
minute post flight data shown). 
[Figure 1 here] 
 Figure 1 shows preflight and postflight mean data for heart rate stroke volume and 
total peripheral resistance during tilt/stand tests before and after both the control and 
midodrine flights.  There were no statistically significant differences between blood 
pressure or cardiac output.  No subject experienced hypotension or presyncope during 
any test.  Hemodynamic responses were very similar between flights.  Of note, however, 
is that mean postflight upright heart rate was significantly higher than the preflight 
baseline for the control flight (p = 0.001), but was not after the midodrine flight (p = 
0.185), compared to their respective preflight upright heart rates.  Importantly, midodrine 
did not result in significantly increased supine or upright blood pressure.  Additionally, 
supine stroke volume (P = 0.056) tended to be higher after midodrine, compared to 
preflight.  Figure 2 shows the individual preflight and postflight heart rate, stroke volume, 
and total peripheral resistances, at time 0 (supine) and after 10 minutes of standing, for 
the control and midodrine flights.    
[Figure 2 here] 
Drug clearance 
 Plasma concentrations of midodrine and the active metabolite de-glymidodrine 
both peaked at times that were reported previously (8,13).  Midodrine peaked at                 
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30 minutes and de-glymidodrine peaked at 90 minutes (data not shown).    
Discussion 
 This study is an essential step towards the implementation of midodrine as a 
countermeasure for post-spaceflight orthostatic hypotension.  The astronauts who 
participated represent the 80% who do not experience orthostatic hypotension because 
they have very high sympathetic responses to upright posture.  Thus the possibility that 
midodrine might raise pressure was real.  If midodrine becomes one of the drugs included 
in the flight formulary, it will be available to all crew members, with flight surgeon 
approval, even those who may not be susceptible to orthostatic hypotension.  For that 
reason, it was necessary to study this group.   
Midodrine did not significantly increase blood pressure in this group of subjects.  
Most studies in which midodrine was reported to increase blood pressure included 
patients with autonomic failure (9), neurally mediated syncope (2,10), hemodialysis-
induced hypotension (11,18), or diabetes (24).Those subjects tended to have supine 
hypertension (3,13); and increased sensitivity to adrenergic agonists due to chronic 
autonomic denervation.  Studies in healthy subjects have shown no (8,10,13) or very 
modest (<10 mmHg) (6,13) changes in arterial pressure.   
There were no striking hemodynamic differences between the control and 
midodrine tilt responses, but the data suggest that midodrine had a modest beneficial 
effect. Although no astronauts were hypotensive following their control flights, increases 
in heart rates during tilt on landing day (Fig 1) indicate that they were less tolerant of the 
procedure than before flight.  They had a less pronounced increase in heart rate following 
midodrine and standing systolic pressure tended to be higher after midodrine (Fig. 1 ).  
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Thus, there was a trend for midodrine to preserve normal upright hemodynamics. 
Limitations 
 The main limitation of this study is the small number of subjects, a fact that is 
exacerbated by the current lack of shuttle flights.  We addressed this difficulty by using 
each astronaut as his own control.  A second limitation is that an average of ~1604 days 
elapsed between the control flight and the midodrine flight.  We have previously shown 
that there is a high degree of reproducibility between post-flight tilt tests (12), for flight 
that were separated by an average of 708 days.  It may be possible that the extended 
amount of time between flights in the current study influenced our results.   
Summary 
A single, 10 mg oral dose of midodrine did not significantly increase blood 
pressure in male, non-presyncopal astronauts and tended to improve tolerance to the 
postflight tilt test.  These results, combined with bed rest studies, a case report 
describing post-spaceflight results in a presyncopal astronaut, as well as many 
clinical reports showing the efficacy of midodrine for orthostatic hypotension 
(16,17,19), suggest that midodrine may help prevent postflight syncope.  It appeared to 
be safe in these five astronauts.  Midodrine could potentially be available to all astronauts 
between time of ignition and landing (possibly at entry interface), thus allowing for the 
maximal benefit at landing.  Individual use would be determined by the flight surgeon, 
depending on specific conditions.   
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 FIGURE LEGENDS 
 
FIGURE 1.  Mean preflight (●) and landing day (○) heart rate, stroke volume and total 
peripheral resistance measurements during supine rest and 10 minutes of tilt/stand for 
control flight (left panels) and midodrine flight (right panels).  Bars represent SEM. * = p 
= 0.001; $ = p = 0.056.   
 
FIGURE 2.  Individual preflight (●) and landing day (○) heart rate, stroke volume and 
total peripheral resistance measurements at supine rest and 10 minutes of tilt/stand for 
measurements during supine rest and tilt for control flight (left panels) and midodrine 
flight (right panels).  
 
